Prev Arrow Stocks

10x Genomics, Inc. ($TXG) Stock Forecast: Down 6.9% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is 10x Genomics, Inc.?

A company specializing in single cell and spatial biology, 10x Genomics (TXG) is recognized for its innovative technologies within the genomics industry. The stock witnessed significant bearish movement today in light of recent market developments.

Why is 10x Genomics, Inc. going down?

TXG stock is down 6.9% on Jul 18, 2024 13:56

  • The injunction impacting NanoString's CosMx Spatial Molecular Imager products in Germany, resulting from an ongoing patent dispute with 10x Genomics, potentially triggered concerns among investors, contributing to a pessimistic sentiment surrounding TXG.
  • Despite optimistic price targets from Wall Street analysts pointing towards substantial upside potential, the stock registered a notable decline, suggesting possible market skepticism or uncertainty.
  • The anticipated second-quarter 2024 financial results announcement could serve as a critical event influencing investor sentiment and adding to the volatility witnessed in TXG's stock price.
  • The strong performance of Fulgent Genetics and the absence of significant strength in earnings estimate revisions for TXG likely factored into the bearish movement observed today.

TXG Price Chart

TXG News

Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately

Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher Regional Court, in order to suspend an injunction that had been impacting sales of CosMx Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This development is connected with ongoing patent litigation with 10x Genomics, during an appeal process in Germany. Jetzt den vollständigen Artikel lesen

https://www.wallstreet-online.de/nachricht/18284511-bruker-announces-that-injunction-impacting-nanostring-s-cosmx-spatial-molecular-imager-products-germany-has-been-suspended-effective-immediately

News Article Image Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately

Fulgent Genetics ( FLGT ) Soars 6.6%: Is Further Upside Left in the Stock?

Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2304052/fulgent-genetics-flgt-soars-66-is-further-upside-left-in-the-stock

News Article Image Fulgent Genetics  ( FLGT )  Soars 6.6%: Is Further Upside Left in the Stock?

Does 10x Genomics ( TXG ) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?

The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

https://www.zacks.com/stock/news/2303462/does-10x-genomics-txg-have-the-potential-to-rally-8565-as-wall-street-analysts-expect

News Article Image Does 10x Genomics  ( TXG )  Have the Potential to Rally 85.65% as Wall Street Analysts Expect?

10x Genomics ( TXG ) Surges 8.2%: Is This an Indication of Further Gains?

10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2300685/10x-genomics-txg-surges-82-is-this-an-indication-of-further-gains

News Article Image 10x Genomics  ( TXG )  Surges 8.2%: Is This an Indication of Further Gains?

10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company…

https://www.prnewswire.com/news-releases/10x-genomics-to-report-second-quarter-2024-financial-results-on-august-8-2024-302195451.html

News Article Image 10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

10x Genomics, Inc. Price History

18.06.2024 - TXG Stock was down 6.9%

  • The injunction impacting NanoString's CosMx Spatial Molecular Imager products in Germany, resulting from an ongoing patent dispute with 10x Genomics, potentially triggered concerns among investors, contributing to a pessimistic sentiment surrounding TXG.
  • Despite optimistic price targets from Wall Street analysts pointing towards substantial upside potential, the stock registered a notable decline, suggesting possible market skepticism or uncertainty.
  • The anticipated second-quarter 2024 financial results announcement could serve as a critical event influencing investor sentiment and adding to the volatility witnessed in TXG's stock price.
  • The strong performance of Fulgent Genetics and the absence of significant strength in earnings estimate revisions for TXG likely factored into the bearish movement observed today.

17.06.2024 - TXG Stock was up 7.3%

  • The bullish movement in TXG could be attributed to the potential upside suggested by Wall Street analysts, hinting at an 85.7% rally in the stock.
  • The surge in share price and above-average trading volume could be a reflection of investor optimism and confidence in the company's future growth prospects.
  • The appointment of Sarah A. Teichmann, a distinguished academic and research leader, to the board of 10x Genomics might have also contributed to the positive market sentiment, signaling strong leadership and expertise within the company.
  • Additionally, the news of Cathie Wood's ARK Invest buying shares of 10x Genomics could have further boosted investor confidence, especially given Wood's reputation for identifying high-growth potential companies.

16.06.2024 - TXG Stock was up 5.2%

  • The surge in TXG's stock price could be attributed to the positive market sentiment following the announcement of Sarah A. Teichmann joining the company's board, which might be seen as a strategic move to enhance its research capabilities.
  • Additionally, the news of Cathie Wood's ARK Invest buying shares of 10x Genomics could have boosted investor confidence in the company's growth potential, contributing to the bullish movement.
  • The upcoming financial results announcement for the second quarter could also be creating anticipation among investors, leading to increased buying activity and driving the stock price higher.
  • Despite the positive momentum, the stock might have been impacted by the broader market reaction to another company's acquisition, which could have caused some volatility in the sector, including a temporary dip in TXG's share price.

12.06.2024 - TXG Stock was up 5.2%

  • The announcement of 10x Genomics reporting their second-quarter financial results soon could have sparked investor optimism about the company's performance.
  • The addition of Sarah Teichmann, a distinguished academic, to the board may have increased confidence in the company's strategic direction and leadership.
  • Cathie Wood's ARK investing in 10x Genomics could have brought positive attention to the stock, indicating strong growth potential.
  • Despite Illumina's acquisition of a competitor leading to a temporary dip in TXG shares, the overall market sentiment seems to have rebounded, possibly due to investors seeing 10x Genomics as a strong player in the industry with innovative products.

11.06.2024 - TXG Stock was up 9.4%

  • TXG experienced a significant increase in value today despite some recent negative developments.
  • Investor confidence in the stock may have been influenced by ARK Invest's purchase of shares in 10x Genomics led by Cathie Wood.
  • Although the purchase of Fluent BioSciences by Illumina Inc. initially led to a decrease in TXG shares, market sentiment quickly shifted to a positive outlook.
  • Despite challenges including reduced revenues and substantial losses, TXG exceeded expectations by demonstrating resilience and rallying upwards.

10.06.2024 - TXG Stock was down 11.9%

  • TXG recorded a notable decline of 14%.
  • Various factors may have contributed to this decline:
  • Recent updates about a collaboration with Illumina potentially falling short of investor expectations.
  • Furthermore, a downgrade from Deutsche Bank could have fueled the downward pressure on the stock.
  • This series of events likely prompted negative reactions from market participants, resulting in the significant drop in TXG's share price.

10.06.2024 - TXG Stock was down 11.9%

  • TXG likely experienced a bearish movement due to disappointing Q3 results, similar to another company's situation.
  • The positive news about VivoPower International securing a loan extension may have diverted investor attention away from TXG, contributing to its bearish movement.
  • Market sentiment towards biotech stocks might have also played a role in TXG's decline, especially if there were broader concerns about the sector's performance today.

28.05.2024 - TXG Stock was up 5.4%

  • The uptick in TXG stock today might be linked to increased purchases by notable investor Cathie Wood's ARK Invest, indicating confidence in the company's growth potential.
  • ARK Invest's choice to reallocate investments from companies like Teladoc, Zoom, and NVIDIA towards TXG and Roku could have also influenced the positive movement in 10x Genomics stock.
  • The growing interest from ARK Invest in 10x Genomics may be seen by investors as a positive sign for the company's future performance, resulting in heightened buying activity and an increase in stock price.

13.05.2024 - TXG Stock was down 5.1%

  • A prominent investor reduced its stake in the company, potentially indicating doubt about its future prospects.
  • This development may have caused worry among other investors regarding the company's growth and financial performance.
  • The resulting sell-off from the investor's actions likely played a role in TXG's bearish movement in the stock price.

10.04.2024 - TXG Stock was up 6.5%

  • The positive movement in TXG's stock today may be linked to a recent legal victory at the German Federal Patent Court, invalidating a patent claimed by 10x Genomics. This win potentially strengthened investor confidence in the company's intellectual property rights and competitive standing.
  • Discussions on the role of nanotechnology across various industries and its projected market growth might have also influenced the positive outlook on TXG, positioning the company favorably to take advantage of this expanding market.
  • Attention from Cathie Wood towards nanotech stocks and her focus on identifying future growth prospects could have directed interest towards companies like TXG, contributing to the upward trend in the stock price.
  • Insights into TXG's international revenue performance and its impact on financial analysts' projections likely offered further understanding of the company's growth potential, reinforcing investor confidence and propelling the stock's upward trajectory.

09.04.2024 - TXG Stock was up 5.2%

  • The bullish movement in TXG stock today may be linked to NanoString Technologies Germany GmbH's legal victory over 10x Genomics in the German Federal Patent Court, which invalidated a key patent. This development likely increased investor confidence in NanoString (now a Bruker business) and its future prospects, leading to positive sentiment towards related companies in the genomics industry like TXG.
  • Cathie Wood's interest in innovative companies like TXG might have also influenced the positive market movement, as her endorsement often garners investor attention and drives up stock prices.
  • The analysis of TXG's international revenue performance within the broader market context could have provided additional insights into the company's growth potential, further boosting investor optimism and contributing to the bullish trend in the stock.

07.04.2024 - TXG Stock was down 5.3%

  • The decline in 10x Genomics (TXG) stock today could be due to various reasons:
  • Recent underperformance by a well-known investor in high-growth biotech stocks may have shaken investor confidence in TXG.
  • Concerns about international revenue and executive stock sales may have contributed to negative investor sentiment.
  • Despite positive developments in the gene editing sector, cautious market behavior could be influenced by broader market conditions and internal activities at 10x Genomics.
  • Disappointment stemming from the Q1 2024 earnings call transcript, lacking a clear positive catalyst, might have triggered a sell-off of TXG shares.

03.04.2024 - TXG Stock was up 5.2%

  • The positive financial results reported for the first quarter of 2024, with revenue increasing by 5%, likely fueled the bullish movement in TXG stock today.
  • Advances in gene editing technologies and potential treatments for various genetic disorders have contributed to the overall bullish sentiment in gene editing stocks, potentially influencing the positive market movement of TXG.
  • Investor interest and confidence in 10x Genomics may have been generated by speculation surrounding insider moves and executives reevaluating stock sale strategies, influencing the company's future prospects.
  • Anticipation for the upcoming earnings announcement for Q1 2024, with revenue estimates indicating a year-over-year increase, could have further enhanced investor optimism and contributed to the bullish trend in TXG stock.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.